GIPR and Obesity: Available in oral and injectable formulation, and, more recently, GLP-1R-GIPR co-agonists, such as tirzepatide (at 10 mg or 15 mg), are all recommended on the American Diabetes Association (ADA) Professional Practice Committee guidance for obesity and weight management for the prevention of type 2 diabetes [10].